<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660643</url>
  </required_header>
  <id_info>
    <org_study_id>17247</org_study_id>
    <secondary_id>I8F-MC-GPHN</secondary_id>
    <nct_id>NCT04660643</nct_id>
  </id_info>
  <brief_title>A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss</brief_title>
  <acronym>SURMOUNT-4</acronym>
  <official_title>Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of tirzepatide in participants with obesity or overweight. The main purpose&#xD;
      is to learn more about how tirzepatide maintains body weight loss. The study has two phases:&#xD;
      a lead-in phase in which all participants take tirzepatide and a treatment phase in which&#xD;
      participants will either continue tirzepatide or switch to placebo. The study will last about&#xD;
      2 years (25 visits).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">May 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 19, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change from Randomization (Week 36) in Body Weight</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Percent change from randomization in body weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Body Weight</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Change from randomization in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Waist Circumference</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Change from randomization in waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Maintain ≥80% of the Body Weight Lost During the Open-Label Period</measure>
    <time_frame>Week 88</time_frame>
    <description>Percentage of participants who maintain ≥80% of the body weight lost during the open-label period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve ≥5% Body Weight Reduction</measure>
    <time_frame>Week 88</time_frame>
    <description>Percentage of participants who achieve ≥5% body weight reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve ≥10% Body Weight Reduction</measure>
    <time_frame>Week 88</time_frame>
    <description>Percentage of participants who achieve ≥10% body weight reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of Participants Returning to &gt;95% Baseline Weight for Those Who Lost ≥5% during the Open-Label Period</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Time to first occurrence of participants returning to &gt;95% baseline weight for those who lost ≥5% during the open-label period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Randomization in Body Weight</measure>
    <time_frame>Randomization, Week 64</time_frame>
    <description>Percent change from randomization in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Body Mass Index (BMI)</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Change from randomization in BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Fasting Glucose</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Change from randomization in fasting glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Change from randomization in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Fasting Insulin</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Change from randomization in fasting insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Total Cholesterol</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Change from randomization in total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Low Density Lipoprotein (LDL) Cholesterol</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Change from randomization in LDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in High Density Lipoprotein (HDL) Cholesterol</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Change from randomization in HDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Very Low Density Lipoprotein (VLDL) Cholesterol</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Change from randomization in VLDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Triglycerides</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Change from randomization in triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Free Fatty Acids</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Change from randomization in free fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Systolic Blood Pressure (SBP)</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Change from randomization in SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>Change from randomization in DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Short Form 36 Version 2 Health Survey (SF 36v2) Acute Form Physical Functioning Domain Score</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life (HRQoL) on 8 domains; 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning 7) limitations in usual role due to emotional problems; and 8) general mental health. Domain scores are norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10, with higher scores indicating better levels of function and/or better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score</measure>
    <time_frame>Randomization, Week 88</time_frame>
    <description>The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5 item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. Individual composite scale scores and a total score can be computed and are presented on a scale of 0 to 100, with higher scores indicating better function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Body Weight</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Percent change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in BMI</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Change from baseline in BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve ≥15% Body Weight Reduction</measure>
    <time_frame>Week 88</time_frame>
    <description>Percentage of participants who achieve ≥15% body weight reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Waist Circumference</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Change from baseline in waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Glucose</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Change from baseline in fasting glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HbA1c</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Change from baseline in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Insulin</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Change from baseline in fasting insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Total Cholesterol</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Change from baseline in total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HDL Cholesterol</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Change from baseline in HDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in LDL Cholesterol</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Change from baseline in LDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in VLDL Cholesterol</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Change from baseline in VLDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Triglycerides</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Change from baseline in triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Free Fatty Acids</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Change from baseline in free fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SBP</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Change from baseline in SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in DBP</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>Change from baseline in DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in SF 36v2 Acute Form Physical Functioning Domain Score</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>The SF-36v2 acute form, 1-week recall assesses participants' HRQoL on 8 domains; 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning 7) limitations in usual role due to emotional problems; and 8) general mental health. Domain scores are norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10, with higher scores indicating better levels of function and/or better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in IWQOL-Lite-CT Physical Function Composite Score</measure>
    <time_frame>Baseline, Week 88</time_frame>
    <description>The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5 item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. Individual composite scale scores and a total score can be computed and are presented on a scale of 0 to 100, with higher scores indicating better function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Tirzepatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Tirzepatide</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and&#xD;
             previous diagnosis with at least one of the following comorbidities: hypertension,&#xD;
             dyslipidemia, obstructive sleep apnea, cardiovascular disease&#xD;
&#xD;
          -  History of at least one unsuccessful dietary effort to lose body weight&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Change in body weight greater than 5 kg within 3 months prior to starting study&#xD;
&#xD;
          -  Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of&#xD;
             obesity&#xD;
&#xD;
          -  History of pancreatitis&#xD;
&#xD;
          -  Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine&#xD;
             neoplasia syndrome type 2 (MEN-2)&#xD;
&#xD;
          -  History of significant active or unstable major depressive disorder (MDD) or other&#xD;
             severe psychiatric disorder within the last 2 years&#xD;
&#xD;
          -  Any lifetime history of a suicide attempt&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cahaba Research</name>
      <address>
        <city>Pelham</city>
        <state>Alabama</state>
        <zip>35124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Memorial Hospital La Jolla</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Wilshire</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Investigators, Inc.</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New West Physicians Clinical Research</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optumcare Colorado Springs - Monument</name>
      <address>
        <city>Monument</city>
        <state>Colorado</state>
        <zip>80132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Partners Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Clinical Research Institute</name>
      <address>
        <city>Margate</city>
        <state>Florida</state>
        <zip>33063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine Research Solutions, Inc.</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKY Clinical Research Network Group-Blake</name>
      <address>
        <city>Union City</city>
        <state>Georgia</state>
        <zip>30291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East-West Medical Research Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Clinical Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network - Chicago</name>
      <address>
        <city>Flossmoor</city>
        <state>Illinois</state>
        <zip>60422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Specialists</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute For Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana, LLC - New Albany</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Clinic</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L-MARC Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Group</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute (MedStar Physician Based Research Network)</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices and Research</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcturus Healthcare , PLC, Troy Internal Medicine Research Division</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>StudyMetrix Research</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glacier View Research Institute - Endocrinology</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Medical Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmQuest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center (WFUBMC)</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lillestol Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intend Research, LLC</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Area Research, LLC</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tribe Clinical Research, LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biopharma Informatic, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Hills Family Medicine/North Hills Medical Research</name>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <zip>76180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Houston Heart Center</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads, Inc.</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Clinical Research Center</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEDIC</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1060ABN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Viamonte</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1120AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stat Research S.A.</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aire</city>
        <state>Buenos Aires</state>
        <zip>C1023AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mautalen Salud e Investigación</name>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Autónoma De Buenos Aire</state>
        <zip>C1128AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Dr Laura Maffei Investigacion Clinica Aplicada</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <state>Ciudad Autónoma De Buenos Aire</state>
        <zip>C1425AGC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Médico Catamarca IMEC</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asociación de Beneficencia Hospital Sirio Libanés</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1419AHN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEDOES</name>
      <address>
        <city>Vitória</city>
        <state>Espírito Santo</state>
        <zip>29055450</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cline Research Center</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80030-480</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Núcleo de Pesquisa Clínica do Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90430-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Sao Lucas</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13034-685</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BR Trials - Ensaios Clinicos e Consultoria</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>03325-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISPEM - Instituto São José dos Campos em Pesquisas Médicas</name>
      <address>
        <city>São José dos Campos</city>
        <state>São Paulo</state>
        <zip>12243-280</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IBPClin - Instituto Brasil de Pesquisa Clínica</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22241-180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPQuali Pesquisa Clínica</name>
      <address>
        <city>São Paulo</city>
        <zip>01228-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Endocrinologia Alcantara Gonzalez</name>
      <address>
        <city>Bayamon</city>
        <zip>00959</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Dr. Martha Gomez Cuellar</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellness clinical Research Vega Baja</name>
      <address>
        <city>Vega Baja</city>
        <zip>00694</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng-Kung Uni. Hosp.</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Puerto Rico</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
  </removed_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/aK2GGZSCqbdJMNUlhfAVV</url>
    <description>A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss (SURMOUNT-4)</description>
  </link>
  <verification_date>October 1, 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolism and Nutrition Disorder</keyword>
  <keyword>Prediabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirzepatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

